Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection

Massimo Libra, Daniela Capello, Annunziata Gloghini, Pasqualucci Laura, Eva Berra, Michaela Cerri, Daniela Gasparotto, Stivala Franca, Valli De Re, Gianluca Gaidano, Antonino Carbone

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatitis C virus (HCV) and aberrant somatic hypermutation (SHM) have each been suggested to contribute to the development of B-cell non-Hodgkin's lymphoma (NHL). The incidence of PIM-1, PAX-5, RhoH/TTF, and c-MYC mutations in tumour biopsy specimens from 32 HCV-infected B-cell NHL patients was analysed to determine whether the extent of aberrant SHM among these patients differed from that previously reported for HCV-negative B-cell NHL patients. Mutation of PIM-1, PAX-5, RhoH/TTF, and c-MYC was detected in 4 (13%), 5 (16%), 4 (13%), and 4 (13%) of 32 samples, respectively. In HCV-positive B-cell NHL patients, the frequency of aberrant SHM was lower than that already found in HCV-negative B-cell NHL patients. This indicates that, unlike B-cell lymphomas from HCV-negative patients, aberrant SHM may not contribute significantly to malignant transformation in HCV-associated B-cell lymphomas.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalJournal of Pathology
Volume206
Issue number1
DOIs
Publication statusPublished - May 2005

Keywords

  • Aberrant SHM
  • B-NHL
  • HCV

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection'. Together they form a unique fingerprint.

Cite this